Skip to main content

Biologic monotherapy in the treatment of rheumatoid arthritis

19Citations
Citations of this article
73Readers
Mendeley users who have this article in their library.

Abstract

Biologics, possibly in combination with a conventional disease-modifying antirheumatic drug (DMARD) – preferably methotrexate (MTX), are used in accordance with the recommendations of the international rheumatological societies. However, in clinical practice, this recommendation is often problematic, as many rheumatologists know from personal experience. The quality of life of the patient is affected mainly by drug-induced intolerances (eg, MTX). Thus, the acceptance of the patient to treatment is often so inadequate that a discontinuation of the drug is necessary. In daily practice, approximately 30% of patients with biological therapy receive no concomitant DMARD according to the register data

Cite

CITATION STYLE

APA

Detert, J., & Klaus, P. (2015). Biologic monotherapy in the treatment of rheumatoid arthritis. Biologics: Targets and Therapy, 9, 35–43. https://doi.org/10.2147/BTT.S53361

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free